Table 2.
Overview on currently active vaccines against COVID-19 (Source: https://www.covid-19vaccinetracker.org/).
| Name | Producer | Description |
|---|---|---|
| Ad26.COV2.S | Janssen Pharmaceutical Companies | Non replicating viral vector, for emergency use in the US. |
| mRNA-1273 | Moderna | RNA; LNP-encapsulated mRNA, used in Canada, Israel, Switzerland, EU, the US, and the UK. |
| BNT162b2 | Pfizer/BioNTech | 3 LNP-mRNAs, approved by the European Commission and in Argentina, Mexico, Saudi Arabia, Canada, Bahrain, the US, and UK. |
| AZD1222 | AstraZeneca/University of Oxford | Non replicating viral vector, used in Argentina, Brazil, Dominican Republic, El Salvador, India, Mexico, Morocco, Pakistan, and the UK. |
| Sputnik V | Gamaleya Research Institute | Adeno-based, used in Algeria, Argentina, Bolivia, Hungary, Palestine, Paraguay, Serbia, Turkmenistan, UAE, and Venezuela, and registered in Belarus and Russia. |
| Petrovax | Beijing Institute of Biotechnology | Non-replicating viral vector, for the military by China's Central Military Commission; several countries with emergency use. |
| Unnamed | Research Institute for Biological Safety Problems, Republic of Kazakhstan | Inactivated virus, used through temporary registration in Kazakhstan. |
| Sinopharm/W | Wuhan Institute of Biological Products | Inactivated virus, for emergency use in China and the UAE. |
| Sinopharm/B | Beijing Institute of Biological Products | Inactivated virus, used in Bahrain, China, Pakistan, and the UAE. Several countries with emergency use. |
| Sinovac | Instituto Butantan/Bio Farma | Inactivated virus, for emergency use in Brazil, China, and Indonesia. |
| COVAXIN | Bharat Biotech/Indian Council of Medical Research | Inactivated virus, for emergency use in India, Nepal, and Zimbabwe. |